<DOC>
	<DOCNO>NCT02724917</DOCNO>
	<brief_summary>The purpose study patient schizophrenia evaluate safety , tolerability , pharmacokinetics 3 dos ( low , mid , high ) APN1125 compare placebo administer repeat daily oral dos .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics APN1125 Subjects With Schizophrenia</brief_title>
	<detailed_description>The purpose study evaluate safety profile , tolerability pharmacokinetics ( PK ) APN1125 follow 14 day once-daily oral dose subject schizophrenia stable second-generation antipsychotic therapy . This randomized , double-blind , 2-week , multiple ascend dose study APN1125 . This study enroll three sequential cohort subject diagnose schizophrenia , randomly assign receive one three dos ( low , medium , high ) APN1125 match placebo . Following admission Early Phase Clinical Unit ( EPCU ) , APN1125 administer daily 2 week . All subject remain confined EPCU total 20 day , consist admission , dose observation period .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Males female race 18 45 year age , inclusive Diagnosed schizophrenia , define Diagnostic Statistical Manual Mental Disorders , Fifth Edition ( DSM5 ) , nonacute ( e.g. , chronic ) phase clinically stable least 12 week screen Currently stable secondgeneration antipsychotic regimen ( stable dose medication 12 week ) Subjects ( male female ) childbearing potential must use two effective method contraception start time provide informed consent throughout duration study 3 month discharge Women childbearing potential must negative pregnancy test screen admission Clinically significant abnormal serum electrolyte ( sodium , potassium , calcium , magnesium ) repeat test Insulindependent diabetes insufficiently control diabetes mellitus judgment Investigator Renal insufficiency serum creatinine &gt; 1.6 mg/dL Malignant tumor within 5 year Screening exception treat squamous basal cell carcinoma , cervical carcinoma situ , brachytherapy localized prostate cancer Female subject pregnant , breastfeeding , plan become pregnant study Unstable medical condition clinically significant judgment Investigator Body mass index ( BMI ) &gt; 38 kg/m^2 Screening ALT AST &gt; 1.5 time upper limit normal Positive serology hepatitis B surface antigen , hepatitis C antibody , human immunodeficiency virus ( HIV ) 1 and/or 2 antibody Untreated clinically significant hypo hyperthyroidism ; treat hypo hyperthyroidism stable least 8 week prior Screening History myocardial infarction unstable angina within 6 month Screening Cardiovascular disease history include symptomatic hypotension ( supine systolic blood pressure [ SBP ] &lt; 90 mmHg supine diastolic blood pressure [ DBP ] &lt; 60 mmHg ) , symptomatic orthostatic hypotension ( orthostatic change SBP &gt; 20 mmHg DBP &gt; 15 mmHg ) , hypertension ( supine SBP &gt; 160 mmHg supine DBP &gt; 95 mmHg ) significant cardiac arrhythmia ( judgment Investigator ) Clinically significant abnormality Screening Baseline electrocardiogram ( ECG ) , include necessarily limit confirm QTcF ( QT interval correct heart rate use Fridericia 's formula ) interval value &gt; 450 msec male &gt; 470 msec female Current treatment 2 atypical antipsychotic Psychiatric hospitalization due breakthrough psychotic symptom acute exacerbation within 3 month Day 1 . Subjects recent `` social '' hospitalization may screen consultation Medical Monitor . Subjects DSM5 disorder ineligible comorbid condition clinically unstable primary focus treatment within 3 month prior Screening Subjects meet DSM5 criterion moderate severe alcohol substance use disorder ( nicotine caffeinerelated disorder ) within 6 month prior Screening Urine drug screen ( UDS ) positive drug abuse ( exclude prescribe benzodiazepine ) positive alcohol breath test Screening and/or Baseline ( may repeat , judgment Investigator , subject meet DSM5 criterion moderate severe substance abuse disorder ) Significant suicide risk define 1 ) suicidal ideation endorse item 4 5 ColumbiaSuicide Severity Rating Scale ( CSSRS ) within year prior Screening Baseline , 2 ) suicidal behavior within 2 year prior Screening , 3 ) Investigator assessment History stroke , brain tumor , subdural hematoma , Parkinson 's Disease , dementia clinically significant neurological condition Head trauma loss consciousness within 12 month prior Screening Active acute chronic CNS infection History seizure disorder Immunosuppressants , include systemic corticosteroid ( administer immunosuppressant dose judgment Investigator ) ( Note : Inhaled , nasal , topical steroid use allergy inflammation permit ) Any drug CNS activity ( Note : Occasional ( need ) use sedativehypnotic ( e.g. , benzodiazepine nonbenzodiazepine [ e.g. , zolpidem , zaleplon , zopiclone , eszopiclone ] ) sleep aid stable second generation psychotic permit ) Prohibited antipsychotic medication ( e.g. , clozapine typical , firstgeneration antipsychotic ) Excessive alcohol consumption ( regular alcohol intake 14 unit per week ) history alcohol use disorder . Use alcohol 48 hour admission EPCU allow . Failure inability perform Screening Baseline assessments Exposure experimental drug experimental medical device within 2 month Screening , experimental biologic within 3 month Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>